Fierce Pharma April 24, 2024
The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. But, thanks to blockbuster meds across wider disease areas and other challenges, the lucrative market may soon slow down for the first time in years.
According to Evaluate’s 2024 report, “Orphan Drugs are Losing Their Sparkle,” the category is set to pick up $185 billion this year and some $270 billion by 2028.
Yet, sales growth is notably shrinking. The meds averaged an almost 11% sales increase in the decade ending in 2023 but will “barely hit double digits” through 2030.
Several factors come into play to dull orphan drugs’ shine, such as the “blazing return of big drugs for big diseases,”...
Today's Sponsors
Today's Sponsor